Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price hit a new 52-week low on Tuesday . The stock traded as low as $176.77 and last traded at $181.34, with a volume of 40071 shares trading hands. The stock had previously closed at $186.15.
Genmab A/S Stock Up 2.0 %
The stock has a market cap of $12.06 billion, a price-to-earnings ratio of 10.42 and a beta of 1.10. The company has a 50 day simple moving average of $203.42 and a 200-day simple moving average of $211.96.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
